Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for acquiring information on condition of patient with interstitial pneumonia and use thereof

A related information and interstitial technology, applied in the field of obtaining information about the condition of patients with interstitial pneumonia, can solve the problem of difficult identification of CTD-ILD and IIPs

Pending Publication Date: 2020-10-30
SAPPORO MEDICAL UNIVERSITY +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, it is not easy to distinguish CTD-ILD from IIPs in clinical practice

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for acquiring information on condition of patient with interstitial pneumonia and use thereof
  • Method for acquiring information on condition of patient with interstitial pneumonia and use thereof
  • Method for acquiring information on condition of patient with interstitial pneumonia and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] (1) Biological samples

[0134] As the biological sample, the serum of 102 patients with interstitial pneumonia was used. Among 102 patients, 16 were diagnosed with CTD-ILD (CTD-ILD group), 35 were diagnosed with IPAF (IPAF group), and 51 were diagnosed with IPF (IPF group) .

[0135] (2) Determination of biomarkers

[0136] (2.1) Determination of CXCL9

[0137] The following R1 to R5 reagents were used to measure the concentration of CXCL9 in the serum of each patient using a fully automatic immunoassay device HISCL-5000 or HISCL-2000i (Sysmex Corporation).

[0138] ·R1 reagent

[0139] The anti-MIG monoclonal antibody (RANDOX) was digested with pepsin or IdeS protease by conventional methods to obtain Fab fragments. The Fab fragments are labeled with biotin in a conventional method, and dissolved in a buffer containing 1% bovine serum albumin (BSA) and 0.5% casein to obtain R1 reagent.

[0140] ·R2 reagent

[0141] The magnetic particles with streptavidin immobilized on the sur...

Embodiment 2

[0152] (1) Identification of CTD-ILD and IPAF

[0153] By ROC analysis, for the CXCL9 concentration and CXCL10 concentration in the serum, the optimal cut-off value for distinguishing the CTD-ILD group (16 persons) and the IPAF group (35 persons) of Example 1 was determined. Calculate the sensitivity, specificity and area under the curve (AUC) of the judgment using the set cutoff value. In this determination, when the concentration of CXCL9 or CXCL10 is the same as or higher than the cut-off value, the patient is determined to be CTD-ILD. In addition, when the concentration of CXCL9 or CXCL10 is lower than the cut-off value, it is determined that the patient is not CTD-ILD. The ROC curve obtained is shown in Figure 7 and 8 . Table 1 shows the cut-off value (pg / mL), sensitivity (%), specificity (%) and AUC of each biomarker.

[0154] 【Table 1】

[0155] Biomarkers Cutoff Sensitivity (%) Specificity (%) AUC CXCL932.587490.72 CXCL10287.160800.75

[0156] According to Table 1, ...

Embodiment 3

[0164] (1) Biological samples

[0165] As the biological sample, the serum of the patient with interstitial pneumonia of Example 1 was used.

[0166] (2) Determination of biomarkers

[0167] (2.1) Determination of CXCL9 and CXCL10

[0168] As the CXCL9 and CXCL10 concentration values ​​in the serum of each patient, the measured values ​​obtained in Example 1 were used.

[0169] (2.2) Determination of KL-6

[0170] The concentration of KL-6 in the serum of each patient was measured using HISCL KL-6 reagent (Sekisui Medical Co., Ltd.) and ISCL-5000 or HISCL-2000i (Cysemex Corporation). The measurement procedure of KL-6 is the same as the measurement of CXCL9 in Example 1. The HISCL KL-6 reagent includes R1 reagent containing biotin-labeled mouse anti-KL-6 monoclonal antibody, R2 reagent containing STA-bound magnetic particles, and R3 reagent containing ALP-labeled mouse anti-KL-6 monoclonal antibody. The HISCL R4 reagent of the measurement buffer, the HISCL R5 reagent containing CDP-Sta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a method for acquiring information on a condition of a patient with interstitial pneumonia and application thereof. The present invention addresses the problem of providing ameans capable of identifying the condition of a patient suffering from interstitial pneumonia. The method comprises steps of measuring at least one biomarker in a biological sample of an interstitialpneumonia patient, the biomarker including at least one selected from CXCL9 and CXCL10, a measurement result of the biomarker serving as an index for discrimination between IPAF and CTD-ILD.

Description

Technical field [0001] The present invention relates to a method for obtaining disease-related information of patients with interstitial pneumonia. In addition, the present invention relates to a method for determining the condition of a patient with interstitial pneumonia. Further, the present invention relates to kits used in these methods, devices and computer programs for determining the condition of patients with interstitial pneumonia. Background technique [0002] Interstitial pneumonia is a disease in which inflammation and fibrosis occur in the interstitial tissue of the lung, especially the alveolar wall. If interstitial pneumonia progresses, symptoms such as decreased vital capacity and gas exchange capacity and difficulty breathing due to pulmonary fibrosis. The causes of interstitial pneumonia involve many aspects. For example, interstitial pneumonia that occurs with collagen disease as the underlying disease is called Connective tissue disease associated intersti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G16B20/00G16H50/20G01N33/68
CPCG16B20/00G16H50/20G01N33/6863G01N2800/12G01N33/6893G01N2333/7158
Inventor 龟田优美大塚满雄长谷川武宏
Owner SAPPORO MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com